Relationship of Immune-Related Adverse Events with Tumor Response and Prognosis in Esophageal Squamous Cell Carcinoma Following Nivolumab Monotherapy
Grade1/2 irAEs during the entire treatment period and within 8 weeks of nivolumab initiation were significantly associated with improved tumor response and survival in patients with advanced ESCC treated with nivolumab monotherapy. Therefore, mild irAEs may be predictive markers for the response and prognosis of ESCC following ICI treatment.
Authors
- Manato Ohsawa (ORCID: https://orcid.org/0000-0002-6357-1412)
- Ryosuke Hirohata (ORCID: https://orcid.org/0000-0003-2226-8019)
- Yoichi Hamai (ORCID: https://orcid.org/0000-0002-7945-734X)
- Yuta Ibuki (ORCID: https://orcid.org/0000-0002-6028-6018)
- Nao Kitasaki (ORCID: https://orcid.org/0000-0002-2801-8566)
- Manabu Emi
- Morihito Okada (ORCID: https://orcid.org/0000-0002-0601-3828)
- Tomoaki Kurokawa
Institutions
- Hiroshima University (JP)
Publication Details
- Journal
- Cancers
- Published
- 2024-10-18
- DOI
- https://doi.org/10.3390/cancers16203529
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.70